Addressing unmet needs in rare diseases and systemic complement mediated disorders

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenienc

A leader in the field of engineered protease biopharmaceuticals

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Protease engineering platform – hemophilia assets in development and a SQ systemic complement research program

Essential Medicines for Hemophilia
and other rare bleeding disorders

Greater Convenience

Next Generation Protease Drugs

Learn more about our Pipeline

Hemophilia A or B w Inhibitors – ToB
Phase 3
FVIID/Glanzmann/Hemlibra – ToB
Phase 1/2
Anti-C3 protease for Dry AMD
Preclinical
 
Preclinical
 
Preclinical
 
Preclinical
Hemophilia B (rFIX)
Phase 2
Hemophilia B FIX Gene Therapy
Preclinical

Protease Engineering Platform

 

Complement

CB 2782-PEG

IVT Anti-C3 Dry AMD

CB 4332 SQ Enhanced CFI

SQ Systemic Complement Degraders

 

Protease Medicines

The Catalyst Advantage

Drug candidates for severe medical conditions

Learn more about the medicines we are developing

See our pipeline

Addressing diseases with unmet medical needs

Share our passion about treating disease

See our publications 

Experienced and passionate team

Learn more about the Catalyst team and mission/culture

Meet the team